Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Emulate Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 3 distinct examiners and 2 distinct art units. This indicates that while each action has a unique examiner, at least two of those examiners are working within the same art unit. The distribution of 3 pending office actions across 3 distinct examiners means that no single reviewer is handling multiple cases.
WASHINGTON, BRITNEY NICOLE is the busiest examiner, with 1 pending office action. The presence of 2 distinct art units for 3 pending actions suggests some concentration of the company's biotechnology research. Practitioners should note that with 3 distinct examiners, the company will face three different individual perspectives during the prosecution process. Managing 3 pending office actions across 2 distinct art units requires a strategy that accounts for both individual examiner styles and broader art unit policies.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WASHINGTON, BRITNEY NICOLE | 1 | 83.1% | +13.2% |
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
| SINES, BRIAN J | 1 | 80.1% | +5.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18520821 | CONTROLLING PRESSURE | SINES, BRIAN J | 55d |
| 18659536 | ORGANS-ON-CHIPS AS A PLATFORM FOR EPIGENETICS DISCOVERY | WASHINGTON, BRITNEY NICOLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18591819 | HOST-BIOME INTERACTIONS | AFREMOVA, VERA | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18591819 | HOST-BIOME INTERACTIONS | AFREMOVA, VERA | 4d overdue |
| 18659536 | ORGANS-ON-CHIPS AS A PLATFORM FOR EPIGENETICS DISCOVERY | WASHINGTON, BRITNEY NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18659536 | ORGANS-ON-CHIPS AS A PLATFORM FOR EPIGENETICS DISCOVERY | WASHINGTON, BRITNEY NICOLE | — | §102 | Non-Final OA | — | Pending | May 09, 2024 |
| 18591819 | HOST-BIOME INTERACTIONS | AFREMOVA, VERA | 1653 | §102§112 | Non-Final OA | 4d overdue | Pending | Feb 29, 2024 |
| 18520821 | CONTROLLING PRESSURE | SINES, BRIAN J | 1796 | §103 | Non-Final OA | 55d | Pending | Nov 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial